Suppliers / Hubei Honch Pharmaceutical

Hubei Honch Pharmaceutical

China Updated 9 July 2026

Hubei Honch Pharmaceutical is an API manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 10 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 20 March 2025 as VAI.

11
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 20 March 2025 VAI US FDA
  • 22 March 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3009478588

What they file, and where

Molecule Regulators Docs
Vinblastine US FDA 2
Bleomycin US FDA 1
Bortezomib US FDA 1
Fidaxomicin US FDA 1
Melphalan US FDA 1
Midostaurin US FDA 1
Mitomycin US FDA 1
Staurosporine US FDA 1
Vincristine US FDA 1
Vinorelbine US FDA 1

Also appears on these molecule pages

Bortezomib API Melphalan API Midostaurin API Vincristine API Vinorelbine API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Hubei Honch Pharmaceutical

Does Hubei Honch Pharmaceutical hold a US DMF or a CEP?
Hubei Honch Pharmaceutical holds 11 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Hubei Honch Pharmaceutical FDA-registered?
One site operated by Hubei Honch Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Hubei Honch Pharmaceutical's last inspection go?
The most recent inspection on record closed on 20 March 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 2 inspections are on file.
Where does Hubei Honch Pharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Hubei Honch Pharmaceutical make?
10 molecules are on record against Hubei Honch Pharmaceutical, including Vinblastine, Bleomycin, Bortezomib and Fidaxomicin. Each links through to that molecule's full manufacturer list.
Which regulators recognise Hubei Honch Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Hubei Honch Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 20 March 2025.

Comparable suppliers

Hetero shares 3 molecules MSN Laboratories shares 2 molecules Dr Reddy's Laboratories shares 2 molecules Biophore India Pharmaceuticals shares 2 molecules Shilpa Pharma Lifesciences shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates